Elon Musk reportedly contacts TSMC, Intel CEO Pat Gelsinger quickly responds: Terafab collaboration continues
Intel (INTC.US) CEO Patrick Gelsinger stated that the company will continue its collaboration with Elon Musk on the Terafab project.
Zhitong Finance APP reported that Intel (INTC.US) CEO Pat Gelsinger stated that the company will continue to cooperate with Elon Musk on the Terafab project. This is a bold attempt by the billionaire to venture into advanced chip manufacturing.
Earlier this week, Musk said he was in talks with TSMC regarding collaboration on Terafab. This news dampened investor sentiment towards Intel—the company had signed on as a development partner for Terafab in April this year.
Pat Gelsinger told the media before an event in Tokyo commemorating the US company's 50th anniversary in the Japanese market that Intel would continue to participate in the Terafab project.
The Terafab project is part of a global wave of governments and enterprises racing to expand production capacity for semiconductors and other key components, which are essential for accelerating the rollout of artificial intelligence applications.
From ball bearings, chip equipment, and industrial chemicals to sliding rails, the production capacities of factories for all types of products have reached their limits, prompting companies to build more production lines.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gold Price Forecast: XAU/USD retraces gains and nears two-month lows at $4,104
BUZZ-Caribou shares plunge as company explores sale and cancels cancer project
October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72 ** Caribou Biosciences announced late Tuesday that it is exploring strategic options, including a potential sale, merger, or other transactions, to maximize shareholder value ** Caribou said it plans to halt development of its allogeneic CAR-T cell therapy programs, including vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma ** Caribou also stated it will lay off employees and cut costs, with most layoffs expected to be completed by Q4 2026 ** As of June 30, the company held $113.8 millions in cash, cash equivalents, and marketable securities ** As of the previous trading day's close, the company's share price had dropped about 28% year-to-date (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them only for reader convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)
Australian Dollar: Neutral outlook inside tight range against US Dollar – UOB
Crypto prices
More
